Sign In
Buy ADMA
$8.69
+0.120 (+1.40%)
At Close: Jun 23, 2026
Will Strong Asceniv Sales Drive ADMA Biologics Further?
09:16am, Friday, 27'th Jun 2025
ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
09:56am, Wednesday, 25'th Jun 2025
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
06:51pm, Friday, 20'th Jun 2025
Adma Biologics (ADMA) closed the most recent trading day at $17.74, moving 2.15% from the previous trading session.
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
02:10pm, Monday, 16'th Jun 2025
ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.
ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade)
04:11am, Sunday, 15'th Jun 2025
ADMA's revenue growth has plateaued over the last three quarters, raising concerns about near-term momentum and justifying a shift to a neutral stance. Despite strong fundamentals and a promising long
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?
11:41am, Friday, 06'th Jun 2025
ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?
11:06am, Wednesday, 28'th May 2025
At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.
ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss
03:54am, Friday, 09'th May 2025
ADMA Biologics has demonstrated significant revenue growth, margin expansion, and profitability, leading to a 1,314% increase in share price since 2021. The company's Q1 performance showed a 40% YoY r
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
02:30pm, Thursday, 08'th May 2025
ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025.
ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript
11:05pm, Wednesday, 07'th May 2025
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossm
Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates
06:25pm, Wednesday, 07'th May 2025
Adma Biologics (ADMA) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.08 per share a year ago.
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
04:05pm, Wednesday, 07'th May 2025
1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue ( 1 ) of $118.6 Million), a 40% YoY Increase
3 Mid-Cap Medical Stocks Outperforming the Market
12:50pm, Tuesday, 06'th May 2025
While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biote
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus
09:25am, Monday, 05'th May 2025
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Adma Biologics (ADMA) Increases Yet Falls Behind Market: What Investors Need to Know
06:50pm, Friday, 02'nd May 2025
Adma Biologics (ADMA) concluded the recent trading session at $23.52, signifying a +1.07% move from its prior day's close.
